BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 23408627)

  • 1. Immunogenicity of a vaccine regimen composed of simian immunodeficiency virus DNA, rMVA, and viral particles administered to female rhesus macaques via four different mucosal routes.
    Manrique M; Kozlowski PA; Cobo-Molinos A; Wang SW; Wilson RL; Montefiori DC; Carville A; Aldovini A
    J Virol; 2013 Apr; 87(8):4738-50. PubMed ID: 23408627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge.
    Kwa S; Lai L; Gangadhara S; Siddiqui M; Pillai VB; Labranche C; Yu T; Moss B; Montefiori DC; Robinson HL; Kozlowski PA; Amara RR
    J Virol; 2014 Sep; 88(17):9579-89. PubMed ID: 24920805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.
    Iyer SS; Gangadhara S; Victor B; Shen X; Chen X; Nabi R; Kasturi SP; Sabula MJ; Labranche CC; Reddy PB; Tomaras GD; Montefiori DC; Moss B; Spearman P; Pulendran B; Kozlowski PA; Amara RR
    J Virol; 2016 Oct; 90(19):8842-54. PubMed ID: 27466414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques.
    Stevceva L; Alvarez X; Lackner AA; Tryniszewska E; Kelsall B; Nacsa J; Tartaglia J; Strober W; Franchini G
    J Virol; 2002 Nov; 76(22):11659-76. PubMed ID: 12388726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV.
    Van Rompay KK; Abel K; Earl P; Kozlowski PA; Easlick J; Moore J; Buonocore-Buzzelli L; Schmidt KA; Wilson RL; Simon I; Moss B; Rose N; Rose J; Marthas ML
    Vaccine; 2010 Feb; 28(6):1481-92. PubMed ID: 19995539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251.
    Lü X; Kiyono H; Lu D; Kawabata S; Torten J; Srinivasan S; Dailey PJ; McGhee JR; Lehner T; Miller CJ
    AIDS; 1998 Jan; 12(1):1-10. PubMed ID: 9456249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term control of simian immunodeficiency virus mac251 viremia to undetectable levels in half of infected female rhesus macaques nasally vaccinated with simian immunodeficiency virus DNA/recombinant modified vaccinia virus Ankara.
    Manrique M; Kozlowski PA; Cobo-Molinos A; Wang SW; Wilson RL; Montefiori DC; Mansfield KG; Carville A; Aldovini A
    J Immunol; 2011 Mar; 186(6):3581-93. PubMed ID: 21317390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine-Elicited Mucosal and Systemic Antibody Responses Are Associated with Reduced Simian Immunodeficiency Viremia in Infant Rhesus Macaques.
    Jensen K; Nabi R; Van Rompay KKA; Robichaux S; Lifson JD; Piatak M; Jacobs WR; Fennelly G; Canfield D; Mollan KR; Hudgens MG; Larsen MH; Amedee AM; Kozlowski PA; De Paris K
    J Virol; 2016 Aug; 90(16):7285-7302. PubMed ID: 27252535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates.
    Bertley FM; Kozlowski PA; Wang SW; Chappelle J; Patel J; Sonuyi O; Mazzara G; Montefiori D; Carville A; Mansfield KG; Aldovini A
    J Immunol; 2004 Mar; 172(6):3745-57. PubMed ID: 15004179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques.
    Marthas ML; Van Rompay KK; Abbott Z; Earl P; Buonocore-Buzzelli L; Moss B; Rose NF; Rose JK; Kozlowski PA; Abel K
    Vaccine; 2011 Apr; 29(17):3124-37. PubMed ID: 21377510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal and systemic SIV-specific cytotoxic CD4
    Khanna M; Jackson RJ; Alcantara S; Amarasena TH; Li Z; Kelleher AD; Kent SJ; Ranasinghe C
    Sci Rep; 2019 Apr; 9(1):5661. PubMed ID: 30952887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.
    Horton H; Vogel TU; Carter DK; Vielhuber K; Fuller DH; Shipley T; Fuller JT; Kunstman KJ; Sutter G; Montefiori DC; Erfle V; Desrosiers RC; Wilson N; Picker LJ; Wolinsky SM; Wang C; Allison DB; Watkins DI
    J Virol; 2002 Jul; 76(14):7187-202. PubMed ID: 12072518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen.
    Winstone N; Wilson AJ; Morrow G; Boggiano C; Chiuchiolo MJ; Lopez M; Kemelman M; Ginsberg AA; Mullen K; Coleman JW; Wu CD; Narpala S; Ouellette I; Dean HJ; Lin F; Sardesai NY; Cassamasa H; McBride D; Felber BK; Pavlakis GN; Schultz A; Hudgens MG; King CR; Zamb TJ; Parks CL; McDermott AB
    J Virol; 2011 Sep; 85(18):9578-87. PubMed ID: 21734035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses.
    Vargas-Inchaustegui DA; Tuero I; Mohanram V; Musich T; Pegu P; Valentin A; Sui Y; Rosati M; Bear J; Venzon DJ; Kulkarni V; Alicea C; Pilkington GR; Liyanage NP; Demberg T; Gordon SN; Wang Y; Hogg AE; Frey B; Patterson LJ; DiPasquale J; Montefiori DC; Sardesai NY; Reed SG; Berzofsky JA; Franchini G; Felber BK; Pavlakis GN; Robert-Guroff M
    Clin Immunol; 2014 Aug; 153(2):308-22. PubMed ID: 24907411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques.
    Malkevitch N; Patterson LJ; Aldrich K; Richardson E; Alvord WG; Robert-Guroff M
    J Immunol; 2003 Apr; 170(8):4281-9. PubMed ID: 12682263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
    Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
    Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.
    Zhao J; Pinczewski J; Gómez-Román VR; Venzon D; Kalyanaraman VS; Markham PD; Aldrich K; Moake M; Montefiori DC; Lou Y; Pavlakis GN; Robert-Guroff M
    J Virol; 2003 Aug; 77(15):8354-65. PubMed ID: 12857905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
    Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses.
    Lai L; Kwa SF; Kozlowski PA; Montefiori DC; Nolen TL; Hudgens MG; Johnson WE; Ferrari G; Hirsch VM; Felber BK; Pavlakis GN; Earl PL; Moss B; Amara RR; Robinson HL
    Vaccine; 2012 Feb; 30(9):1737-45. PubMed ID: 22178526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination of Macaques with DNA Followed by Adenoviral Vectors Encoding Simian Immunodeficiency Virus (SIV) Gag Alone Delays Infection by Repeated Mucosal Challenge with SIV.
    Almond N; Berry N; Stebbings R; Preston M; Ham C; Page M; Ferguson D; Rose N; Li B; Mee ET; Hassall M; Stahl-Hennig C; Athanasopoulos T; Papagatsias T; Herath S; Benlahrech A; Dickson G; Meiser A; Patterson S
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31413132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.